Zhejiang Teruisi Pharmaceutical Inc.

1207, Building 3, 1366 Hongfeng Road, Huzhou, Zhejiang, China

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 3

33.3%

Phase 2

16.7%

Trial Status Distribution

Active, not recruiting

16.7%

Completed

16.7%

Not yet recruiting

33.3%

Unknown

33.3%

Clinical Trials

Trials sponsored by this organization (6)

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Phase 2

Not yet recruiting

interventional

Sep 2025139 participants

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Phase 1

Not yet recruiting

interventional

Sep 202566 participants

A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

Phase 3

Unknown

interventional

Aug 2022126 participants

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Phase 1

Active, not recruiting

interventional

Sep 2020147 participants

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Phase 3

Unknown

interventional

Aug 2020608 participants

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

Phase 1

Completed

interventional

Jun 2018114 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations